These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

943 related items for PubMed ID: 22575238

  • 1. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP, Greenberg RE, Steinberg GD.
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [Abstract] [Full Text] [Related]

  • 2. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
    Steinberg GD, Smith ND, Ryder K, Strangman NM, Slater SJ.
    Postgrad Med; 2011 May; 123(3):28-34. PubMed ID: 21566413
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
    Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M.
    J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
    [Abstract] [Full Text] [Related]

  • 4. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P, European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [Abstract] [Full Text] [Related]

  • 5. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G, Birkhäuser FD, Recker F, Thalmann GN, Studer UE.
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G.
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [Abstract] [Full Text] [Related]

  • 12. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
    Barlow L, McKiernan J, Sawczuk I, Benson M.
    BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 14. Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
    McElree IM, Packiam VT, Steinberg RL, Mott SL, Gellhaus PT, Nepple KG, O'Donnell MA.
    J Urol; 2022 Nov; 208(5):969-977. PubMed ID: 35830552
    [Abstract] [Full Text] [Related]

  • 15. Valrubicin in refractory non-muscle invasive bladder cancer.
    Sharma P, Zargar-Shoshtari K, Sexton WJ.
    Expert Rev Anticancer Ther; 2015 Nov; 15(12):1379-87. PubMed ID: 26569509
    [Abstract] [Full Text] [Related]

  • 16. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D, von Wietersheim J, Pflüger H, Steiner H, Doehn C, Büttner H, Böhle A, Kausch I.
    Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
    Mugiya S, Nagata M, Takayama T, Ozono S, Ito T, Maruyama S, Hadano S, Nagae H.
    Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
    Lee JY, Diaz RR, Cho KS, Lim MS, Chung JS, Kim WT, Ham WS, Choi YD.
    J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.